Tirzepatide noninferior to dulaglutide for CV outcomes in type 2 diabetes
Tirzepatide is noninferior to dulaglutide with respect to a composite of death from cardiovascular (CV) causes, myocardial infarction, or stroke among patients with type 2 diabetes and atherosclerotic CV disease, according ...
Dec 30, 2025
0
0









